THOR MEDICAL ASA (TRMED.OL) Stock Fundamental Analysis
Europe - Euronext Oslo - OSL:TRMED - NO0010597883 - Common Stock
5.05 NOK
+0.02 (+0.4%)
Taking everything into account, TRMED scores 0 out of 10 in our fundamental rating. TRMED was compared to 85 industry peers in the Biotechnology industry. TRMED has a bad profitability rating. Also its financial health evaluation is rather negative. TRMED does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past 5 years TRMED always reported negative net income.
- TRMED had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- TRMED has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for TRMED so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- TRMED has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for TRMED has been increased compared to 5 years ago.
- Compared to 1 year ago, TRMED has a worse debt to assets ratio.
2.2 Solvency
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | N/A |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | N/A | ||
| Quick Ratio | N/A |
3. Growth
3.1 Past
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- TRMED does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
THOR MEDICAL ASA / TRMED.OL FAQ
Can you provide the ChartMill fundamental rating for THOR MEDICAL ASA?
ChartMill assigns a fundamental rating of 0 / 10 to TRMED.OL.
What is the valuation status of THOR MEDICAL ASA (TRMED.OL) stock?
ChartMill assigns a valuation rating of 0 / 10 to THOR MEDICAL ASA (TRMED.OL). This can be considered as Overvalued.
What is the profitability of TRMED stock?
THOR MEDICAL ASA (TRMED.OL) has a profitability rating of 0 / 10.